Alnylam Pharmaceuticals (NASDAQ:ALNY) Insider Sells $755,340.12 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) insider Melissa Mclaughlin sold 2,286 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the sale, the insider directly owned 9,443 shares in the company, valued at $3,120,156.06. This trade represents a 19.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Melissa Mclaughlin also recently made the following trade(s):

• On Thursday, April 2nd, Melissa Mclaughlin sold 1,624 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $319.59, for a total transaction of $519,014.16.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY traded down $10.82 on Tuesday, reaching $319.52. 1,305,095 shares of the company’s stock were exchanged, compared to its average volume of 1,372,175. The firm has a market capitalization of $42.37 billion, a price-to-earnings ratio of 186.85 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The business’s 50-day moving average is $326.15 and its two-hundred day moving average is $393.92. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period last year, the company posted ($0.65) earnings per share. The firm’s revenue for the quarter was up 84.9% on a year-over-year basis. As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Groupama Asset Managment boosted its position in shares of Alnylam Pharmaceuticals by 160.4% during the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after purchasing an additional 2,483,697 shares in the last quarter. Norges Bank bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $895,816,000. Arrowstreet Capital Limited Partnership boosted its position in shares of Alnylam Pharmaceuticals by 698.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after purchasing an additional 1,185,909 shares in the last quarter. Qube Research & Technologies Ltd bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $369,943,000. Finally, Holocene Advisors LP bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $194,616,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

ALNY has been the subject of several recent analyst reports. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, March 21st. Barclays initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 target price for the company. Weiss Ratings cut shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday. Morgan Stanley decreased their target price on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research report on Friday, January 30th. Finally, Needham & Company LLC lowered their target price on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $473.87.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.